Subacute Cutaneous Lupus Erythematosus Clinical Trials

8 clinical trials for Subacute Cutaneous Lupus Erythematosus across international registries, including 4 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A Long-Term Extension Study to Learn More About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus — RECRUITING · PHASE3
• A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY, TOLERABILITY, AND EFFICACY OF IMVT-1402 IN PARTICIPANTS WITH ACTIVE SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS (SCLE) AND/OR CHRONIC CUTANEOUS LUPUS ERYTHEMATOSUS (CCLE) WITH OR WITHOUT SYSTEMIC MANIFESTATIONS — RECRUITING · PHASE2
• A 2-PART SEAMLESS PART A (PHASE 2)/PART B (PHASE 3) RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BIIB059 IN PARTICIPANTS WITH ACTIVE SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS AND/OR CHRONIC CUTANEOUS LUPUS ERYTHEMATOSUS WITH OR WITHOUT SYSTEMIC MANIFESTATIONS AND REFRACTORY AND/OR INTOLERANT TO ANTIMALARIAL THERAPY (AMETHYST — RECRUITING · PHASE3
• A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, PROOF OF CONCEPT STUDY ASSESSING THE EFFICACY AND SAFETY OF THE RIPK1-INHIBITOR SAR443122 IN PATIENTS WITH MODERATE TO SEVERE SUBACUTE OR DISCOID/CHRONIC CUTANEOUS LUPUS ERYTHEMATOSUS — RECRUITING
• A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus — ACTIVE_NOT_RECRUITING · PHASE2
• A Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants With Cutaneous Lupus Erythematosus (CLE) — ACTIVE_NOT_RECRUITING · PHASE2
• Safety and Efficacy of KRP203 in Subacute Cutaneous Lupus Erythematosus — COMPLETED · PHASE2
• Pilot Tape Harvesting Study — COMPLETED

Refine this search